Literature DB >> 1311943

Azoles, allylamines and drug metabolism.

D J Back1, J F Tjia, S M Abel.   

Abstract

Four antifungal drugs, the azoles ketoconazole, itraconazole and fluconazole, and the allylamine terbinafine, were studied for their effects on the metabolism of cyclosporin A (CyA) and cortisol by human liver microsomes in vitro (n = 3). Ketoconazole produced marked inhibition of CyA hydroxylase (to metabolites M17 and M1) with IC50 and Ki values of 0.24 +/- 0.01 and 0.022 +/- 0.004 microM, respectively. On the basis of the IC50, itraconazole was 10 times less potent (IC50 of 2.2 +/- 0.2 microM), and fluconazole and terbinafine were each above 100 microM. No kinetic parameters were calculated for terbinafine because of the lack of inhibitory effects. Ketoconazole was the most potent inhibitor of cortisol metabolism (to 6 beta-hydroxycortisol, IC50 = 0.6 microM). Itraconazole produced marked inhibition of cortisol metabolism (IC50 = 2.4 microM), but fluconazole and terbinafine had little effect. These data confirm that ketoconazole is a potent inhibitor of cytochrome P-450-IIIA4, and this has clinical relevance. Although the inhibition with fluconazole was much less than with itraconazole at equimolar concentrations, it should be noted that in-vivo plasma concentrations of fluconazole are much greater than that of itraconazole. Clinical interactions of CyA with both fluconazole and itraconazole have been reported; in contrast to these azoles, terbinafine does not have the same interaction potential.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311943     DOI: 10.1111/j.1365-2133.1992.tb00003.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

Review 1.  Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.

Authors:  R Davis; J A Balfour
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

2.  Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.

Authors:  Islam R Younis; Daniel J George; Terence J McManus; Herbert Hurwitz; Patricia Creel; Andrew J Armstrong; Jing Jie Yu; Kristina Bacon; Gerald Hobbs; Cody J Peer; William P Petros
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-12       Impact factor: 3.333

Review 3.  Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences.

Authors:  K T Kivistö; P J Neuvonen; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

Review 4.  Systemic antifungal agents. Drug interactions of clinical significance.

Authors:  E Albengres; H Le Louët; J P Tillement
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

5.  Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.

Authors:  B Lebrun-Vignes; V C Archer; B Diquet; J C Levron; O Chosidow; A J Puech; D Warot
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 6.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

7.  Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.

Authors:  J Ahonen; K T Olkkola; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

Review 8.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

9.  [Onychomycosis].

Authors:  D Reinel
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

Review 10.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.